Neural Cell Adhesion Molecules (Neural Cell Adhesion Molecule)

Cell adhesion molecule involved in a diverse range of contact-mediated interactions among neurons, astrocytes, oligodendrocytes, and myotubes. It is widely but transiently expressed in many tissues early in embryogenesis. Four main isoforms exist, including CD56; (CD56 ANTIGEN); but there are many other variants resulting from alternative splicing and post-translational modifications. (From Pigott & Power, The Adhesion Molecule FactsBook, 1993, pp115-119)

Also Known As:

Networked: 1091 relevant articles (17 outcomes, 128 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Gerardy-Schahn, Rita: 16 articles (12/2017 - 08/2003)
2.	Schachner, Melitta: 16 articles (01/2016 - 10/2002)
3.	Bock, Elisabeth: 11 articles (01/2019 - 01/2002)
4.	Kaur, Gurcharan: 11 articles (01/2019 - 05/2003)
5.	Berezin, Vladimir: 11 articles (12/2012 - 01/2002)
6.	Hildebrandt, Herbert: 10 articles (01/2022 - 08/2003)
7.	Mühlenhoff, Martina: 10 articles (12/2017 - 08/2004)
8.	Maness, Patricia F: 9 articles (01/2017 - 05/2003)
9.	Diehl, Katharina: 8 articles (01/2022 - 09/2017)
10.	Görig, Tatiana: 8 articles (01/2022 - 09/2017)

Related Diseases

1.	Neoplasms (Cancer) 10/01/2017 - "This work presents evidence that NCAM targeting can highly increase the efficacy of nanomedicines in the appropriate tumor models." 10/01/1998 - "This study was undertaken to evaluate polysialylated NCAM as a marker helpful in distinguishing between various embryonal tumors and other lesions suspicious of a malignancy. " 01/01/2011 - "In this tissue microarray-based immunohistochemical study, we confirmed the expression of NCAM in Wilms tumors, nephrogenic rests, and metanephric mesenchyme and its early derivatives in fetal renal cortex. " 11/01/2005 - "In the present study, we have aimed to clarify the hypothesis that NCAM-mediated inhibition of salivary gland tumor proliferation is caused by homophilic binding and involves the prevention of signal transduction for perineural invasion using HSG cells. " 05/01/2003 - "Furthermore, in such very few previous studies on NCAM expression in MCC, all the tumor cells were not necessarily demonstrated to express NCAM. "
2.	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 08/15/1997 - "Expression of the neural cell adhesion molecule CD56 is associated with short remission duration and survival in acute myeloid leukemia with t(8;21)(q22;q22)." 01/01/2019 - "Neural cell adhesion molecule 1 (NCAM1; CD56) is expressed in up to 20% of acute myeloid leukemia (AML) patients. " 09/01/2008 - "Association between high expression of natural killer related-genes (NCAM/CD94) and early death during induction in children with acute myeloid leukemia." 05/01/2000 - "The neural cell adhesion molecule, CD56, is expressed on acute myelogenous leukemia (AML) cells in 17-20% of the patients. " 09/01/1997 - "Cerebellar myeloblastoma formation in CD7-positive, neural cell adhesion molecule (CD56)-positive acute myelogenous leukemia (M1)."
3.	Schizophrenia (Dementia Praecox) 07/30/2010 - "In schizophrenia, a significant reduction in the ratio of the two major membrane-bound forms of NCAM (180 and 140) was observed in BA10. " 12/01/2020 - "This study investigated the relationship between the serum NCAM concentrations and hippocampal volume and psychotic symptoms in first-episode drug naïve schizophrenia (FES) patients. " 01/01/1997 - "To investigate the possible involvement of the NCAM gene in schizophrenia, we conducted a comprehensive genetic study, which included linkage analysis and an association study employing the Haplotype Relative Risk (HRR) design in nuclear families. " 01/01/1997 - "NCAM and schizophrenia: genetic studies." 01/01/2023 - "The present review provides the main evidence that support the contribution of autoimmunity and NCAM abnormalities in the development of schizophrenia. "
4.	Neoplasm Metastasis (Metastasis) 10/01/2012 - "Treatment with low-dose ZOL can reduce NCAM expression that may contribute toward reduced spinal cord metastasis, suggesting that NCAM is an alternative therapeutic target and that the low-dose ZOL treatment protocol is a reasonable approach for its treatment." 10/01/2012 - "Low-dose ZOL significantly reduced spinal cord metastasis probably through reduced NCAM expression in vivo. " 10/01/2011 - "Soluble NCAM status was a significant independent factor predictive of long-term survival in patients with HCC, and high levels of soluble NCAM were significantly related to intrahepatic metastasis. " 04/01/2010 - "This cells line, pretreated with an anti-NCAM antibody and inoculated intravenously (i.v.) into syngeneic mice, developed less and smaller lung metastases. " 06/01/2003 - "NCAM expression is of interest both for evaluating the prognosis of patients with conventional RCCs and for determining a subgroup of patients at high risk for adrenal and CNS metastases."
5.	Glioma (Gliomas) 09/25/2015 - "Finally, we found that miR-30a-5p promotes glioma cell growth invasion by repressing NCAM. " 06/01/2007 - "On the other hand, serum NCAM expression was not associated with the main clinicopathological features of gliomas, including overall survival. " 06/01/2007 - "We observed that glioma patients presented higher NCAM HMW and lower NCAM LMW levels than control subjects (P < 0.01). " 12/28/2001 - "All normal brain tissues expressed NCAM; NCAM expression was positive in Grade I-II glioma [95% (19/20)], Grade III glioma [38.9% (7/18)], Grade IV glioma [20% (2/10)] respectively. " 01/01/1999 - "In glioma cell lines, NCAM expression was lost upon passage. "

Related Drugs and Biologics

1.	Neural Cell Adhesion Molecules (Neural Cell Adhesion Molecule)
2.	Synaptophysin
3.	Chromogranin A
4.	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
5.	Glial Cell Line-Derived Neurotrophic Factor (GDNF)
6.	Glial Fibrillary Acidic Protein
7.	Peptides (Polypeptides)
8.	Liposomes (Liposome)
9.	Doxorubicin (Adriamycin)
10.	Dexamethasone (Maxidex)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Intravenous Infusions
3.	Therapeutics
4.	Denervation
5.	Heterologous Transplantation (Xenotransplantation)